BeiGene to Present at Upcoming Investor Conferences
September 25 2018 - 6:00AM
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage
biopharmaceutical company focused on developing and commercializing
innovative molecularly-targeted and immuno-oncology drugs for the
treatment of cancer, today announced that the company will present
at two upcoming investor conferences:
- The Ladenburg Thalmann 2018 Healthcare Conference in New York
City on Tuesday, October 2, at 1 p.m. (ET); and
- The Leerink Partners Roundtable Series: Rare Disease &
Immuno-Oncology in New York City on Wednesday, October 3 at 3 p.m.
(ET).
Live webcasts can be accessed from the investors section of
BeiGene’s website at http://ir.beigene.com/ and archived replays
will be available for 90 days following each event.
About BeiGeneBeiGene is a global,
commercial-stage, research-based biotechnology company focused on
molecularly-targeted and immuno-oncology cancer therapeutics. With
a team of over 1,300 employees in China, the United States,
Australia and Switzerland, BeiGene is advancing a pipeline
consisting of novel oral small molecules and monoclonal antibodies
for cancer. BeiGene is also working to create combination solutions
aimed to have both a meaningful and lasting impact on cancer
patients. BeiGene markets ABRAXANE® (nanoparticle albumin–bound
paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) in
China under a license from Celgene Corporation.i
|
|
Investor
Contact |
Media
Contact |
Craig West |
Liza Heapes |
+1 857-302-5189 |
+ 1 857-302-5663 |
ir@beigene.com |
media@beigene.com |
|
|
i ABRAXANE®, REVLIMID®, and VIDAZA® are registered trademarks of
Celgene Corporation.
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Aug 2024 to Sep 2024
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Sep 2023 to Sep 2024